Verve Therapeutics (VERV) Financials

$4.59 +0.08 (+1.77%)

Closing price 04/17/2025 04:00 PM Eastern

Extended Trading

$4.60 +0.01 (+0.22%)

As of 04/17/2025 06:23 PM Eastern

Annual Income Statements for Verve Therapeutics

This table shows Verve Therapeutics' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2022	2023	2024
Net Income / (Loss) Attributable to Common Shareholders	-157	-200	-199
Consolidated Net Income / (Loss)	-157	-200	-199
Net Income / (Loss) Continuing Operations	-157	-200	-199
Total Pre-Tax Income	-157	-200	-198
Total Operating Income	-166	-223	-229
Total Gross Profit	1.94	12	32
Total Revenue	1.94	12	32
Operating Revenue	1.94	12	32
Total Cost of Revenue	0.00	0.00	0.00
Total Operating Expenses	168	235	261
Selling, General & Admin Expense	38	50	57
Research & Development Expense	130	185	204
Total Other Income / (Expense), net	8.35	23	30
Other Income / (Expense), net	8.35	23	30
Income Tax Expense	0.05	0.28	0.35
Basic Earnings per Share	($2.91)	($3.12)	($2.35)
Weighted Average Basic Shares Outstanding	54.02M	64.18M	84.72M
Diluted Earnings per Share	($2.91)	($3.12)	($2.35)
Weighted Average Diluted Shares Outstanding	54.02M	64.18M	84.72M
Weighted Average Basic & Diluted Shares Outstanding	61.83M	83.62M	88.80M

This table shows Verve Therapeutics' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Net Income / (Loss) Attributable to Common Shareholders	-45	-41	-52	-55	-46	-48	-49	-50	-48	-52
Consolidated Net Income / (Loss)	-45	-41	-52	-54	-46	-48	-49	-50	-50	-50
Net Income / (Loss) Continuing Operations	-45	-41	-52	-54	-46	-48	-49	-50	-50	-50
Total Pre-Tax Income	-45	-41	-52	-54	-46	-48	-49	-50	-50	-50
Total Operating Income	-44	-48	-58	-59	-52	-54	-57	-59	-57	-56
Total Gross Profit	0.93	1.01	1.40	2.09	3.12	5.14	5.70	6.69	6.87	13
Total Revenue	0.93	1.01	1.40	2.09	3.12	5.14	5.70	6.69	6.87	13
Operating Revenue	0.93	1.01	1.40	2.09	3.12	5.14	5.70	6.69	6.87	13
Total Operating Expenses	45	49	60	61	55	59	63	66	64	69
Selling, General & Admin Expense	9.59	11	13	13	12	12	14	15	14	14
Research & Development Expense	35	37	47	47	44	47	48	51	50	55
Total Other Income / (Expense), net	-1.33	6.68	6.28	4.78	6.64	5.63	8.21	9.10	6.88	6.11
Other Income / (Expense), net	-1.33	6.68	6.28	4.78	6.64	5.63	8.21	9.10	6.88	6.11
Income Tax Expense	0.00	-	0.00	0.18	0.07	0.03	0.11	0.07	0.10	0.07
Basic Earnings per Share	($0.79)	($0.66)	($0.84)	($0.87)	($0.72)	($0.69)	($0.59)	($0.59)	($0.59)	($0.58)
Weighted Average Basic Shares Outstanding	57.21M	54.02M	61.79M	61.95M	63.21M	64.18M	83.13M	84.23M	84.63M	84.72M
Diluted Earnings per Share	($0.79)	($0.66)	($0.84)	($0.87)	($0.72)	($0.69)	($0.59)	($0.59)	($0.59)	($0.58)
Weighted Average Diluted Shares Outstanding	57.21M	54.02M	61.79M	61.95M	63.21M	64.18M	83.13M	84.23M	84.63M	84.72M
Weighted Average Basic & Diluted Shares Outstanding	61.60M	61.83M	61.93M	63.72M	63.75M	83.62M	83.97M	84.62M	84.66M	88.80M

This table details how cash moves in and out of Verve Therapeutics' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2022	2023	2024
Net Change in Cash & Equivalents	51	91	-34
Net Cash From Operating Activities	-122	-150	-158
Net Cash From Continuing Operating Activities	-122	-150	-158
Net Income / (Loss) Continuing Operations	-157	-200	-199
Consolidated Net Income / (Loss)	-157	-200	-199
Depreciation Expense	2.80	5.46	6.75
Amortization Expense	-1.03	-14	-12
Non-Cash Adjustments To Reconcile Net Income	25	42	49
Changes in Operating Assets and Liabilities, net	8.38	18	-2.26
Net Cash From Investing Activities	-156	28	75
Net Cash From Continuing Investing Activities	-156	28	75
Purchase of Property, Plant & Equipment	-13	-9.28	-3.74
Purchase of Investments	-479	-517	-424
Sale and/or Maturity of Investments	337	554	503
Net Cash From Financing Activities	329	213	49
Net Cash From Continuing Financing Activities	329	213	49
Repurchase of Common Equity	-0.78	-0.46	-0.07
Issuance of Common Equity	328	212	48
Other Financing Activities, net	2.18	1.20	1.26

This table details how cash moves in and out of Verve Therapeutics' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Net Change in Cash & Equivalents	204	-162	-32	-14	8.28	128	-62	-2.71	17	14
Net Cash From Operating Activities	-29	-33	-49	-48	-12	-41	-43	-34	-40	-41
Net Cash From Continuing Operating Activities	-29	-33	-49	-48	-12	-41	-43	-34	-40	-41
Net Income / (Loss) Continuing Operations	-45	-41	-52	-54	-46	-48	-49	-50	-50	-50
Consolidated Net Income / (Loss)	-45	-41	-52	-54	-46	-48	-49	-50	-50	-50
Depreciation Expense	0.72	0.93	1.13	1.34	1.47	1.52	1.63	1.67	1.75	1.70
Amortization Expense	-0.12	-2.14	-3.86	-3.70	-3.49	-3.34	-3.97	-3.54	-2.75	-2.16
Non-Cash Adjustments To Reconcile Net Income	9.82	6.85	8.92	11	9.75	12	12	12	13	12
Changes in Operating Assets and Liabilities, net	5.60	2.56	-3.31	-2.98	26	-2.22	-4.12	5.83	-1.12	-2.85
Net Cash From Investing Activities	-56	-168	15	33	-12	-8.89	-42	30	57	30
Net Cash From Continuing Investing Activities	-56	-168	15	33	-12	-8.89	-42	30	57	30
Purchase of Property, Plant & Equipment	-2.64	-4.97	-3.38	-2.66	-1.06	-2.19	-0.43	-0.98	-0.94	-1.39
Purchase of Investments	-148	-257	-134	-113	-148	-122	-164	-112	-75	-73
Sale and/or Maturity of Investments	95	94	153	149	137	116	123	143	133	104
Net Cash From Financing Activities	288	40	2.04	1.23	32	177	23	1.30	0.01	25
Net Cash From Continuing Financing Activities	288	40	2.04	1.23	32	177	23	1.30	0.01	25
Issuance of Common Equity	288	39	1.99	0.62	32	178	22	0.42	-	25
Other Financing Activities, net	1.11	0.44	0.12	0.55	0.21	0.32	0.30	0.83	0.01	0.12

This table presents Verve Therapeutics' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2022	2023	2024
Total Assets	679	753	647
Total Current Assets	563	638	543
Cash & Equivalents	115	206	173
Short-Term Investments	439	418	352
Prepaid Expenses	7.34	8.10	15
Other Current Assets	1.01	5.90	3.26
Plant, Property, & Equipment, net	19	23	19
Total Noncurrent Assets	97	92	86
Long-Term Investments	0.00	0.00	0.00
Other Noncurrent Operating Assets	97	92	86
Total Liabilities & Shareholders' Equity	679	753	647
Total Liabilities	128	153	154
Total Current Liabilities	35	37	43
Accounts Payable	2.42	6.64	4.52
Accrued Expenses	21	20	24
Current Deferred Revenue	-	0.00	3.61
Other Current Liabilities	-	10	10
Total Noncurrent Liabilities	93	116	111
Noncurrent Deferred Revenue	20	49	50
Other Noncurrent Operating Liabilities	73	68	61
Commitments & Contingencies	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	551	600	493
Total Preferred & Common Equity	551	600	493
Preferred Stock	0.00	0.00	0.00
Total Common Equity	551	600	493
Common Stock	896	1,144	1,236
Retained Earnings	-344	-544	-743
Accumulated Other Comprehensive Income / (Loss)	-0.69	0.27	0.43

This table presents Verve Therapeutics' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q1 2023	Q2 2023	Q3 2023	Q1 2024	Q2 2024	Q3 2024
Total Assets	673	634	589	612	732	701	664
Total Current Assets	562	518	473	498	620	591	556
Cash & Equivalents	277	84	70	78	144	141	159
Short-Term Investments	274	425	392	407	462	434	381
Prepaid Expenses	9.99	7.70	8.50	9.89	8.19	12	14
Other Current Assets	0.93	1.40	2.09	3.15	5.77	3.04	2.63
Plant, Property, & Equipment, net	15	21	21	21	21	20	20
Total Noncurrent Assets	97	96	95	93	91	90	88
Other Noncurrent Operating Assets	97	96	95	93	91	90	88
Total Liabilities & Shareholders' Equity	673	634	589	612	732	701	664
Total Liabilities	125	125	124	152	149	155	155
Total Current Liabilities	29	34	33	35	31	40	43
Accounts Payable	0.47	3.37	3.15	1.05	3.05	6.83	4.64
Accrued Expenses	20	19	20	23	17	20	22
Current Deferred Revenue	-	-	-	-	1.47	3.48	5.72
Other Current Liabilities	8.90	11	10	10	10	10	10
Total Noncurrent Liabilities	96	91	91	117	118	114	113
Noncurrent Deferred Revenue	20	20	20	49	52	51	51
Other Noncurrent Operating Liabilities	76	71	71	69	66	63	62
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	548	509	465	460	583	546	509
Total Preferred & Common Equity	548	509	465	460	583	546	509
Preferred Stock	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Common Equity	548	509	465	460	583	546	509
Common Stock	852	906	916	957	1,177	1,190	1,200
Retained Earnings	-303	-396	-450	-496	-593	-643	-693
Accumulated Other Comprehensive Income / (Loss)	-0.92	-0.24	-0.75	-0.60	-0.50	-0.62	1.14

This table displays calculated financial ratios and metrics derived from Verve Therapeutics' official financial filings.

Metric	2022	2023	2024
Growth Metrics	-	-	-
Revenue Growth	0.00%	505.77%	174.98%
EBITDA Growth	-32.65%	-34.18%	2.26%
EBIT Growth	-30.77%	-26.99%	0.72%
NOPAT Growth	-90.30%	-34.67%	-2.48%
Net Income Growth	-30.81%	-27.12%	0.68%
EPS Growth	35.04%	-7.22%	24.68%
Operating Cash Flow Growth	-57.08%	-22.25%	-5.45%
Free Cash Flow Firm Growth	-84.96%	2.67%	-24.18%
Invested Capital Growth	359.81%	-404.53%	-26.31%
Revenue Q/Q Growth	108.93%	54.18%	32.53%
EBITDA Q/Q Growth	-8.45%	-3.93%	-0.14%
EBIT Q/Q Growth	-6.57%	-3.79%	-0.83%
NOPAT Q/Q Growth	-10.08%	-2.88%	-0.94%
Net Income Q/Q Growth	-6.60%	-3.77%	-0.85%
EPS Q/Q Growth	-153.99%	-0.97%	4.47%
Operating Cash Flow Q/Q Growth	-4.13%	-5.49%	-0.10%
Free Cash Flow Firm Q/Q Growth	0.00%	4.64%	-1.03%
Invested Capital Q/Q Growth	390.13%	1.65%	1.56%
Profitability Metrics	-	-	-
Gross Margin	100.00%	100.00%	100.00%
EBITDA Margin	-8,014.27%	-1,775.13%	-630.99%
Operating Margin	-8,536.17%	-1,897.64%	-707.23%
EBIT Margin	-8,105.82%	-1,699.21%	-613.51%
Profit (Net Income) Margin	-8,108.55%	-1,701.55%	-614.59%
Tax Burden Percent	100.03%	100.14%	100.18%
Interest Burden Percent	100.00%	100.00%	100.00%
Effective Tax Rate	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	-4,697.48%	0.00%	0.00%
ROIC Less NNEP Spread (ROIC-NNEP)	-4,688.32%	0.00%	0.00%
Return on Net Nonoperating Assets (RNNOA)	4,662.83%	0.00%	0.00%
Return on Equity (ROE)	-34.66%	-34.78%	-36.36%
Cash Return on Invested Capital (CROIC)	-1,583.20%	0.00%	0.00%
Operating Return on Assets (OROA)	-29.59%	-27.91%	-28.34%
Return on Assets (ROA)	-29.60%	-27.94%	-28.39%
Return on Common Equity (ROCE)	-34.66%	-34.78%	-36.36%
Return on Equity Simple (ROE_SIMPLE)	-28.57%	-33.37%	-40.27%
Net Operating Profit after Tax (NOPAT)	-116	-156	-160
NOPAT Margin	-5,975.32%	-1,328.35%	-495.06%
Net Nonoperating Expense Percent (NNEP)	-9.17%	-7.52%	-6.73%
Return On Investment Capital (ROIC_SIMPLE)	-20.61%	-26.05%	-32.44%
Cost of Revenue to Revenue	0.00%	0.00%	0.00%
SG&A Expenses to Revenue	1,933.69%	424.70%	175.20%
R&D to Revenue	6,702.47%	1,572.94%	632.03%
Operating Expenses to Revenue	8,636.17%	1,997.64%	807.23%
Earnings before Interest and Taxes (EBIT)	-157	-200	-198
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-156	-209	-204
Valuation Ratios	-	-	-
Price to Book Value (P/BV)	2.16	1.48	0.97
Price to Tangible Book Value (P/TBV)	2.16	1.48	0.97
Price to Revenue (P/Rev)	614.13	75.58	14.77
Price to Earnings (P/E)	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	80.86	0.00	0.00
Enterprise Value to Revenue (EV/Rev)	334.43	22.52	0.00
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00
Leverage & Solvency	-	-	-
Debt to Equity	0.02	0.00	0.00
Long-Term Debt to Equity	0.00	0.00	0.00
Financial Leverage	-0.99	-1.01	-1.05
Leverage Ratio	1.17	1.24	1.28
Compound Leverage Factor	1.17	1.24	1.28
Debt to Total Capital	2.12%	0.00%	0.00%
Short-Term Debt to Total Capital	2.12%	0.00%	0.00%
Long-Term Debt to Total Capital	0.00%	0.00%	0.00%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%
Common Equity to Total Capital	97.89%	100.00%	100.00%
Debt to EBITDA	-0.08	0.00	0.00
Net Debt to EBITDA	3.49	0.00	0.00
Long-Term Debt to EBITDA	0.00	0.00	0.00
Debt to NOPAT	-0.10	0.00	0.00
Net Debt to NOPAT	4.68	0.00	0.00
Long-Term Debt to NOPAT	0.00	0.00	0.00
Altman Z-Score	5.04	2.57	0.22
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-
Current Ratio	16.05	17.24	12.65
Quick Ratio	15.81	16.86	12.22
Cash Flow Metrics	-	-	-
Free Cash Flow to Firm (FCFF)	-127	-124	-154
Operating Cash Flow to CapEx	-924.52%	-1,611.00%	-4,220.88%
Free Cash Flow to Firm to Interest Expense	0.00	0.00	0.00
Operating Cash Flow to Interest Expense	0.00	0.00	0.00
Operating Cash Flow Less CapEx to Interest Expense	0.00	0.00	0.00
Efficiency Ratios	-	-	-
Asset Turnover	0.00	0.02	0.05
Accounts Receivable Turnover	0.00	0.00	0.00
Inventory Turnover	0.00	0.00	0.00
Fixed Asset Turnover	0.15	0.57	1.57
Accounts Payable Turnover	0.00	0.00	0.00
Days Sales Outstanding (DSO)	0.00	0.00	0.00
Days Inventory Outstanding (DIO)	0.00	0.00	0.00
Days Payable Outstanding (DPO)	0.00	0.00	0.00
Cash Conversion Cycle (CCC)	0.00	0.00	0.00
Capital & Investment Metrics	-	-	-
Invested Capital	8.03	-24	-31
Invested Capital Turnover	0.79	-1.43	-1.17
Increase / (Decrease) in Invested Capital	11	-32	-6.43
Enterprise Value (EV)	649	265	-47
Market Capitalization	1,192	889	478
Book Value per Share	$8.94	$9.40	$5.83
Tangible Book Value per Share	$8.94	$9.40	$5.83
Total Capital	563	600	493
Total Debt	12	0.00	0.00
Total Long-Term Debt	0.00	0.00	0.00
Net Debt	-543	-624	-524
Capital Expenditures (CapEx)	13	9.28	3.74
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-15	-23	-24
Debt-free Net Working Capital (DFNWC)	540	601	500
Net Working Capital (NWC)	528	601	500
Net Nonoperating Expense (NNE)	41	44	39
Net Nonoperating Obligations (NNO)	-543	-624	-524
Total Depreciation and Amortization (D&A)	1.78	-8.93	-5.65
Debt-free, Cash-free Net Working Capital to Revenue	-764.55%	-195.67%	-75.59%
Debt-free Net Working Capital to Revenue	27,819.06%	5,110.93%	1,545.97%
Net Working Capital to Revenue	27,205.77%	5,110.93%	1,545.97%
Earnings Adjustments	-	-	-
Adjusted Basic Earnings per Share	($2.91)	($3.12)	($2.35)
Adjusted Weighted Average Basic Shares Outstanding	54.02M	64.18M	84.72M
Adjusted Diluted Earnings per Share	($2.91)	($3.12)	($2.35)
Adjusted Weighted Average Diluted Shares Outstanding	54.02M	64.18M	84.72M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	61.83M	83.62M	88.80M
Normalized Net Operating Profit after Tax (NOPAT)	-116	-156	-160
Normalized NOPAT Margin	-5,975.32%	-1,328.35%	-495.06%
Pre Tax Income Margin	-8,105.82%	-1,699.21%	-613.51%
Debt Service Ratios	-	-	-
EBIT to Interest Expense	0.00	0.00	0.00
NOPAT to Interest Expense	0.00	0.00	0.00
EBIT Less CapEx to Interest Expense	0.00	0.00	0.00
NOPAT Less CapEx to Interest Expense	0.00	0.00	0.00
Payout Ratios	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%
Augmented Payout Ratio	-0.50%	-0.23%	-0.03%

This table displays calculated financial ratios and metrics derived from Verve Therapeutics' official financial filings.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Growth Metrics	-	-	-	-	-	-	-	-	-	-
Revenue Growth	0.00%	0.00%	0.00%	0.00%	235.52%	408.30%	305.63%	219.73%	120.24%	154.28%
EBITDA Growth	-103.38%	-40.24%	-89.14%	-41.13%	-7.00%	-18.68%	6.83%	8.11%	-6.94%	-0.55%
EBIT Growth	-98.65%	-30.94%	-72.30%	-31.41%	-1.11%	-17.76%	6.44%	7.56%	-9.49%	-3.40%
NOPAT Growth	-86.62%	-46.62%	-82.49%	-38.85%	-19.32%	-13.07%	2.43%	-0.44%	-8.74%	-3.93%
Net Income Growth	-98.65%	-31.11%	-72.30%	-31.84%	-1.26%	-17.69%	6.23%	7.74%	-9.56%	-3.48%
EPS Growth	-68.09%	-108.64%	-35.48%	-3.57%	8.86%	-4.55%	29.76%	32.18%	18.06%	15.94%
Operating Cash Flow Growth	-36.62%	-17.29%	-46.52%	-79.24%	59.52%	-23.68%	12.25%	28.78%	-235.34%	-0.41%
Free Cash Flow Firm Growth	-164.53%	0.00%	-0.55%	11.81%	54.85%	88.12%	51.00%	78.57%	-129.14%	-520.58%
Invested Capital Growth	35.27%	359.81%	-91.71%	-25.36%	-798.34%	-404.53%	-3,052.85%	-1,187.18%	-26.20%	-26.31%
Revenue Q/Q Growth	0.00%	8.93%	38.74%	49.07%	48.93%	65.03%	10.71%	17.51%	2.59%	90.53%
EBITDA Q/Q Growth	-12.04%	5.25%	-29.48%	-2.67%	15.06%	-5.10%	-1.64%	-1.27%	1.14%	1.18%
EBIT Q/Q Growth	-10.36%	9.20%	-26.67%	-3.52%	15.08%	-5.75%	-0.64%	-2.28%	-0.58%	0.13%
NOPAT Q/Q Growth	-3.95%	-8.78%	-22.11%	-0.56%	10.67%	-3.08%	-5.37%	-3.51%	3.28%	1.48%
Net Income Q/Q Growth	-10.36%	9.08%	-26.51%	-3.86%	15.24%	-5.67%	-0.79%	-2.19%	-0.66%	0.20%
EPS Q/Q Growth	5.95%	16.46%	-27.27%	-3.57%	17.24%	4.17%	14.49%	0.00%	0.00%	1.69%
Operating Cash Flow Q/Q Growth	-9.03%	-12.74%	-49.26%	2.31%	75.37%	-244.42%	-5.90%	20.71%	-15.95%	-3.13%
Free Cash Flow Firm Q/Q Growth	29.12%	-38.20%	28.01%	-25.05%	63.71%	63.64%	-196.99%	45.32%	-288.07%	1.53%
Invested Capital Q/Q Growth	-175.21%	390.13%	-90.17%	248.04%	-1,005.21%	1.65%	4.70%	-28.14%	-5.07%	1.56%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-
Gross Margin	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
EBITDA Margin	-4,799.78%	-4,174.70%	-3,896.23%	-2,683.52%	-1,530.64%	-974.75%	-894.91%	-771.22%	-743.19%	-385.45%
Operating Margin	-4,721.21%	-4,714.43%	-4,149.50%	-2,799.00%	-1,678.99%	-1,048.76%	-998.14%	-879.24%	-828.99%	-428.65%
EBIT Margin	-4,864.37%	-4,054.55%	-3,701.92%	-2,570.81%	-1,465.86%	-939.35%	-853.91%	-743.26%	-728.75%	-381.97%
Profit (Net Income) Margin	-4,864.37%	-4,059.78%	-3,701.92%	-2,579.22%	-1,468.01%	-939.97%	-855.77%	-744.25%	-730.27%	-382.53%
Tax Burden Percent	100.00%	100.13%	100.00%	100.33%	100.15%	100.07%	100.22%	100.13%	100.21%	100.15%
Interest Burden Percent	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
Effective Tax Rate	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	0.00%	-2,594.37%	-1,884.42%	-3,316.63%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
ROIC Less NNEP Spread (ROIC-NNEP)	0.00%	-2,592.66%	-1,881.72%	-3,313.19%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Net Nonoperating Assets (RNNOA)	0.00%	2,578.57%	1,858.65%	3,285.24%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Equity (ROE)	-31.65%	-15.80%	-25.77%	-31.39%	-38.24%	-34.78%	-36.03%	-38.10%	-40.67%	-36.36%
Cash Return on Invested Capital (CROIC)	0.00%	-1,583.20%	-2,437.56%	-4,512.23%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Return on Assets (OROA)	-8.34%	-14.80%	-25.18%	-30.61%	-17.39%	-15.43%	-20.05%	-23.79%	-27.86%	-17.64%
Return on Assets (ROA)	-8.34%	-14.82%	-25.18%	-30.71%	-17.41%	-15.44%	-20.10%	-23.82%	-27.92%	-17.67%
Return on Common Equity (ROCE)	-31.65%	-15.80%	-25.77%	-31.39%	-38.24%	-34.78%	-36.03%	-38.10%	-40.67%	-36.36%
Return on Equity Simple (ROE_SIMPLE)	-26.94%	0.00%	-35.17%	-41.32%	-41.88%	0.00%	-33.76%	-35.28%	-38.74%	0.00%
Net Operating Profit after Tax (NOPAT)	-31	-33	-41	-41	-37	-38	-40	-41	-40	-39
NOPAT Margin	-3,304.84%	-3,300.10%	-2,904.65%	-1,959.30%	-1,175.29%	-734.13%	-698.70%	-615.47%	-580.29%	-300.05%
Net Nonoperating Expense Percent (NNEP)	-3.08%	-1.70%	-2.70%	-3.44%	-1.76%	-1.81%	-1.60%	-1.66%	-2.01%	-1.88%
Return On Investment Capital (ROIC_SIMPLE)	-	-5.93%	-	-	-	-6.30%	-	-	-	-7.95%
Cost of Revenue to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
SG&A Expenses to Revenue	1,032.51%	1,130.34%	894.09%	640.99%	374.91%	238.74%	248.69%	217.38%	201.56%	107.78%
R&D to Revenue	3,788.70%	3,684.09%	3,355.41%	2,258.00%	1,404.07%	910.01%	849.45%	761.86%	727.43%	420.86%
Operating Expenses to Revenue	4,821.21%	4,814.43%	4,249.50%	2,899.00%	1,778.99%	1,148.76%	1,098.14%	979.24%	928.99%	528.65%
Earnings before Interest and Taxes (EBIT)	-45	-41	-52	-54	-46	-48	-49	-50	-50	-50
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-45	-42	-55	-56	-48	-50	-51	-52	-51	-50
Valuation Ratios	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	3.76	2.16	1.75	2.50	1.84	1.48	1.45	0.75	0.81	0.97
Price to Tangible Book Value (P/TBV)	3.76	2.16	1.75	2.50	1.84	1.48	1.45	0.75	0.81	0.97
Price to Revenue (P/Rev)	2,216.38	614.13	266.56	213.53	110.80	75.58	52.75	19.84	16.79	14.77
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	0.00	80.86	485.36	254.45	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Revenue (EV/Rev)	1,623.58	334.43	114.48	128.49	47.17	22.52	14.97	0.00	0.00	0.00
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.00	0.02	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to Equity	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Financial Leverage	-1.01	-0.99	-0.99	-0.99	-1.03	-1.01	-1.02	-1.03	-1.06	-1.05
Leverage Ratio	1.16	1.17	1.17	1.20	1.28	1.24	1.25	1.28	1.32	1.28
Compound Leverage Factor	1.16	1.17	1.17	1.20	1.28	1.24	1.25	1.28	1.32	1.28
Debt to Total Capital	0.00%	2.12%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Short-Term Debt to Total Capital	0.00%	2.12%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	100.00%	97.89%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
Debt to EBITDA	0.00	-0.08	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt to EBITDA	0.00	3.49	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Debt to NOPAT	0.00	-0.10	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt to NOPAT	0.00	4.68	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Altman Z-Score	9.95	5.60	4.06	5.16	2.88	3.23	3.04	1.04	0.84	0.98
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-
Current Ratio	19.35	16.05	15.43	14.32	14.41	17.24	19.82	14.64	13.05	12.65
Quick Ratio	18.98	15.81	15.16	14.00	14.03	16.86	19.38	14.27	12.66	12.22
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-32	-45	-32	-40	-15	-5.29	-16	-8.59	-33	-33
Operating Cash Flow to CapEx	-1,106.37%	-662.08%	-1,454.70%	-1,801.73%	-1,113.20%	-1,861.78%	-9,949.65%	-3,485.51%	-4,231.52%	-2,944.85%
Free Cash Flow to Firm to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.00	0.00	0.01	0.01	0.01	0.02	0.02	0.03	0.04	0.05
Accounts Receivable Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Inventory Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Fixed Asset Turnover	0.09	0.15	0.21	0.32	0.42	0.57	0.76	1.00	1.21	1.57
Accounts Payable Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Sales Outstanding (DSO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Inventory Outstanding (DIO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Payable Outstanding (DPO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Cash Conversion Cycle (CCC)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-
Invested Capital	-2.77	8.03	0.79	2.75	-25	-24	-23	-30	-31	-31
Invested Capital Turnover	-0.26	0.79	0.65	1.69	-0.55	-1.43	-1.43	-1.52	-0.87	-1.17
Increase / (Decrease) in Invested Capital	1.51	11	-8.73	-0.93	-22	-32	-24	-33	-6.51	-6.43
Enterprise Value (EV)	1,508	649	383	699	360	265	240	-166	-130	-47
Market Capitalization	2,059	1,192	892	1,161	845	889	847	410	410	478
Book Value per Share	$9.14	$8.94	$8.24	$7.51	$7.22	$9.40	$7.01	$6.50	$6.01	$5.83
Tangible Book Value per Share	$9.14	$8.94	$8.24	$7.51	$7.22	$9.40	$7.01	$6.50	$6.01	$5.83
Total Capital	548	563	509	465	460	600	583	546	509	493
Total Debt	0.00	12	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Long-Term Debt	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt	-551	-543	-509	-462	-485	-624	-606	-576	-540	-524
Capital Expenditures (CapEx)	2.64	4.97	3.38	2.66	1.06	2.19	0.43	0.98	0.94	1.39
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-18	-15	-24	-22	-22	-23	-17	-25	-26	-24
Debt-free Net Working Capital (DFNWC)	533	540	484	440	464	601	589	551	514	500
Net Working Capital (NWC)	533	528	484	440	464	601	589	551	514	500
Net Nonoperating Expense (NNE)	14	7.69	11	13	9.12	11	8.95	8.62	10	11
Net Nonoperating Obligations (NNO)	-551	-543	-509	-462	-485	-624	-606	-576	-540	-524
Total Depreciation and Amortization (D&A)	0.60	-1.22	-2.73	-2.36	-2.02	-1.82	-2.34	-1.87	-0.99	-0.46
Debt-free, Cash-free Net Working Capital to Revenue	-1,948.12%	-764.55%	-731.00%	-412.67%	-282.45%	-195.67%	-108.01%	-123.15%	-107.00%	-75.59%
Debt-free Net Working Capital to Revenue	57,331.75%	27,819.06%	14,476.38%	8,091.85%	6,080.33%	5,110.93%	3,670.21%	2,666.21%	2,106.15%	1,545.97%
Net Working Capital to Revenue	57,331.75%	27,205.77%	14,476.38%	8,091.85%	6,080.33%	5,110.93%	3,670.21%	2,666.21%	2,106.15%	1,545.97%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	($0.79)	($0.66)	($0.84)	($0.87)	($0.72)	($0.69)	($0.59)	($0.59)	($0.59)	($0.58)
Adjusted Weighted Average Basic Shares Outstanding	57.21M	54.02M	61.79M	61.95M	63.21M	64.18M	83.13M	84.23M	84.63M	84.72M
Adjusted Diluted Earnings per Share	($0.79)	($0.66)	($0.84)	($0.87)	($0.72)	($0.69)	($0.59)	($0.59)	($0.59)	($0.58)
Adjusted Weighted Average Diluted Shares Outstanding	57.21M	54.02M	61.79M	61.95M	63.21M	64.18M	83.13M	84.23M	84.63M	84.72M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	61.60M	61.83M	61.93M	63.72M	63.75M	83.62M	83.97M	84.62M	84.66M	88.80M
Normalized Net Operating Profit after Tax (NOPAT)	-31	-33	-41	-41	-37	-38	-40	-41	-40	-39
Normalized NOPAT Margin	-3,304.84%	-3,300.10%	-2,904.65%	-1,959.30%	-1,175.29%	-734.13%	-698.70%	-615.47%	-580.29%	-300.05%
Pre Tax Income Margin	-4,864.37%	-4,054.55%	-3,701.92%	-2,570.81%	-1,465.86%	-939.35%	-853.91%	-743.26%	-728.75%	-381.97%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
EBIT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Payout Ratios	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	-0.41%	-0.50%	-0.47%	0.00%	0.00%	-0.23%	-0.23%	-0.24%	0.00%	-0.03%

Frequently Asked Questions About Verve Therapeutics' Financials

When does Verve Therapeutics's financial year end?

According to the most recent income statement we have on file, Verve Therapeutics' fiscal year ends in December. Their fiscal year 2024 ended on December 31, 2024.

How has Verve Therapeutics' net income changed over the last 2 years?

Verve Therapeutics' net income appears to be on an upward trend, with a most recent value of -$198.71 million in 2024, rising from -$157.39 million in 2022. The previous period was -$200.07 million in 2023.

What is Verve Therapeutics's operating income?

Verve Therapeutics's total operating income in 2024 was -$228.66 million, based on the following breakdown:

Total Gross Profit: $32.33 million
Total Operating Expenses: $260.99 million

How has Verve Therapeutics revenue changed over the last 2 years?

Over the last 2 years, Verve Therapeutics' total revenue changed from $1.94 million in 2022 to $32.33 million in 2024, a change of 1,565.7%.

How much debt does Verve Therapeutics have?

Verve Therapeutics' total liabilities were at $153.99 million at the end of 2024, a 0.5% increase from 2023, and a 20.0% increase since 2022.

How much cash does Verve Therapeutics have?

In the past 2 years, Verve Therapeutics' cash and equivalents has ranged from $115.41 million in 2022 to $206.18 million in 2023, and is currently $172.56 million as of their latest financial filing in 2024.

How has Verve Therapeutics' book value per share changed over the last 2 years?

Over the last 2 years, Verve Therapeutics' book value per share changed from 8.94 in 2022 to 5.83 in 2024, a change of -34.8%.

Related Companies

This page (NASDAQ:VERV) was last updated on 4/20/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Verve Therapeutics (VERV) Financials

Frequently Asked Questions About Verve Therapeutics' Financials

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Verve Therapeutics (VERV) Financials

Annual Income Statements for Verve Therapeutics

Quarterly Income Statements for Verve Therapeutics

Annual Cash Flow Statements for Verve Therapeutics

Quarterly Cash Flow Statements for Verve Therapeutics

Annual Balance Sheets for Verve Therapeutics

Quarterly Balance Sheets for Verve Therapeutics

Annual Metrics and Ratios for Verve Therapeutics

Quarterly Metrics and Ratios for Verve Therapeutics

Frequently Asked Questions About Verve Therapeutics' Financials

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools